Reyes Arranz, Ana García-Noblejas, Carlos Grande, Jimena Cannata-Ortiz, José J. Sánchez, José-Antonio García-Marco, Concepción Aláez, Javier Pérez-Calvo, Pilar Martínez-Sánchez, Blanca Sánchez-González, Miguel-Angel Canales, Eulogio Conde, Alejandro Martín, Eva Arranz, María-José Terol, Antonio Salar, Dolores Caballero. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. haematol [Internet]. 2013Oct.3 [cited 2024Apr.23];98(10):1563-70. Available from: https://haematologica.org/article/view/6807